Ampio Pharmaceuticals Realizing Swift Progress On All Pipeline Fronts

Mon, 03/26/2012 - 13:14 EDT - Seeking Alpha

By VFC: Ampio Pharmaceuticals (AMPE) released positive trial news for Optina in the treatment of Diabetic Macular Edema last week and shares quickly spiked to over the four dollar mark as a result. Although shares have since retreated to under that price, the results solidify a trend that has the company's pipeline of repositioned products on a roll.Before the positive Optina results, Ampio had also informed investors and the medical community that its potential blockbuster product, Ampion, had been successful in multiple trials as an anti-inflammatory. Given the side effects that are carried with today's standard anti-inflammatory treatments, Ampion could come along just at the right time when medical professionals are looking for alternatives.Going for the swift trifecta in the news cycle, this past Thursday Ampio provided an update on its third lead product, Zertane, for the treatment of premature ejaculation.In a deal similar to one announced last yearComplete Story »

Original article
Login or register to post comments

Ampio Pharmaceuticals: Shares Moving On Positive Study Results
By VFC: Heavy volume carried shares of Ampio Pharmaceuticals (AMPE) to well over the four-dollar mark during early trading on Monday after the company announced that interim results from a trial testing Optina as a treatment for Diabetic Macular Edema (DME) were strong enough to justify halting the trial early and moving forward with the FDA's regulatory process.
Ampio Is A Potential Major Player In The Anti-Inflammatory Market
By VFC: For months, Ampio Pharmaceuticals (
Ampio Pharmaceuticals Moving Up Steadily On Pipeline Gains
By VFC: The Ampio Pharmaceuticals (AMPE) pipeline is still trucking along.
Ampio Shares To Rise In Advance Of Optina Data
By Timeless Wealth:Optina™ is effective in treating macular edema, a swelling of the retina that often leads to diabetic blindness, according to a statement by Ampio Pharmaceuticals (AMPE) early on Monday.
Why Ampio's Big Rebound Run May Not Be Done
By M.E. Garza: Shares of Ampio Pharmaceuticals (AMPE) rocketed over 60% to a high of $4.58 on Monday after the company decided to end a study for its ophthalmology drug Optina™ ahead of schedule due to positive preliminary results. The drug developer has been testing the product, which is orally administered, in the treatment of diabetic macular edema.
Ampio Pharmaceuticals Is On The Move
By VFC: A late day price and volume spike placed shares of Ampio Pharmaceuticals (AMPE) more than ten percent higher than where they opened on Wednesday, a notable feat on a day dominated by bleeding red in the markets as the DOW, Nasdaq and S&P were all down by over a percentage point.
Ampio Pharmaceuticals Follows Multiple Pipeline Strategies With Potential
By VFC: Over the past few months Ampio Pharmaceuticals (AMPE) has issued positive updates regarding all of its pipeline fronts, and as a result shares temporarily returned to the four dollar mark before subsiding back to the south of $3.50.
Ampio Pharma Initiates Phase III, Investors Extend Momentum
By Brian L. Wilson:Shares of Ampio Pharmaceuticals (NASDAQ:
Ampio Pharmaceuticals On A Roll With New Licensing Agreement
By VFC: Ampio Pharmaceuticals (AMPE) recorded another solid week last week, breaking through the nine dollar price-per-share barrier while continuing an uptrend that started in mid August.
Ampio Rebounds As Study Results Published In Europe
By VFC: Shares of Ampio Pharmaceuticals (AMPE) have rebounded by roughly three bucks over the past few weeks as many major catalysts are set to materialize later this year and early next.

Main menu

Secondary menu

Ampio Pharmaceuticals Realizing Swift Progress On All Pipeline Fronts

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu